Towards Non-surgical Therapy for Uterine Fibroids: Catechol-O-methyl Transferase Inhibitor Shrinks Uterine Fibroid Lesions in the Eker Rat Model

Overview

Journal Hum Reprod

Publisher Oxford University Press

Specialty Reproductive Medicine

Date 2011 Sep 8

PMID 21896544

Citations 8

Authors

M H Hassan

H Fouad

S Bahashwan

A Al-Hendy

Affiliations

Soon will be listed here.

Abstract

Background: Uterine leiomyomas (fibroids) are the most common pelvic tumors in women. We assessed the potential therapeutic utility of Ro 41-0960, a synthetic catechol-O-methyl transferase inhibitor (COMTI), in the Eker rat.

Methods: We randomized uterine fibroid-bearing Eker rats for treatment with Ro 41-0960 (150 mg/kg/12 h) versus vehicle for 2 and 4 weeks. The fibroids were measured by caliper and subjected to histological evaluation. Urinary levels of 2-hydroxy estrogen (E(2)), 16-hydroxy E2 and DPD (osteoporosis marker) and serum liver enzymes were evaluated. Expressions of Cyclin D1, proliferating cell nuclear antigen (PCNA), Poly [ADP-ribose] polymerase1 (PARP1), tumor suppressor gene (P53) and transforming growth factor (TGFβ3) were assessed in fibroids using immunohistochemical analysis or RT-PCR. Apoptosis was confirmed using terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling (TUNEL).

Results: Ro 41-0960-treated rats exhibited fibroid volumes of 86 ± 7% and 105 ± 12% of initial burden, at 2 and 4 weeks post-treatment, respectively, significantly lower than control group (240 ± 15% and 300 ± 18%; P< 0.01). Ro 41-0960 increased the urinary 2-hydroxy E2/16-hydroxy E(2) ratio, level of p53 mRNA and TUNEL positivity (P< 0.05) and decreased PARP1, PCNA and cyclin D1 proteins and TGFβ3 mRNA (P< 0.05). Ro 41-0960 did not change normal tissue histology, liver functions or urinary DPD level.

Conclusions: Ro 41-0960 (COMTI) arrested growth/shrunk uterine fibroids in Eker rats. This result may be related to modulation of estrogen-dependent genes involved in apoptosis, proliferation and extracellular matrix deposition via accumulation of 2-hydroxy estrogen. The efficacy and safety of Ro 41-0960 in rats suggest its candidacy for treatment of uterine fibroids.

Citing Articles

Pregnancy and its Outcomes in Patients After Uterine Fibroid Embolization: A Systematic Review and Meta-Analysis.

Ghanaati H, Sanaati M, Shakiba M, Bakhshandeh H, Ghavami N, Aro S Cardiovasc Intervent Radiol. 2020; 43(8):1122-1133.

PMID: 32458009 DOI: 10.1007/s00270-020-02521-6.

Alternative Oral Agents in Prophylaxis and Therapy of Uterine Fibroids-An Up-to-Date Review.

Ciebiera M, Lukaszuk K, Meczekalski B, Ciebiera M, Wojtyla C, Slabuszewska-Jozwiak A Int J Mol Sci. 2017; 18(12).

PMID: 29194370 PMC: 5751189. DOI: 10.3390/ijms18122586.

Association of three single nucleotide polymorphisms of ESR1with breast cancer susceptibility: a meta-analysis.

Hu X, Jiang L, Tang C, Ju Y, Jiu L, Wei Y J Biomed Res. 2017; 31(3):213-225.

PMID: 28808214 PMC: 5460609. DOI: 10.7555/JBR.31.20160087.

Application of a Patient Derived Xenograft Model for Predicative Study of Uterine Fibroid Disease.

Fritsch M, Schmidt N, Groticke I, Frisk A, Keator C, Koch M PLoS One. 2015; 10(11):e0142429.

PMID: 26588841 PMC: 4654507. DOI: 10.1371/journal.pone.0142429.

Association of five single nucleotide polymorphisms at 6q25.1 with breast cancer risk in northwestern China.

Zhou L, He N, Feng T, Geng T, Jin T, Chen C Am J Cancer Res. 2015; 5(8):2467-75.

PMID: 26396922 PMC: 4568782.

References

Hara T, Araki H, Kusaka M, Harada M, Cho N, Suzuki N . Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys. J Clin Endocrinol Metab. 2003; 88(4):1697-704. DOI: 10.1210/jc.2002-021065. View

Devanesan P, Todorovic R, Zhao J, Gross M, Rogan E, Cavalieri E . Catechol estrogen conjugates and DNA adducts in the kidney of male Syrian golden hamsters treated with 4-hydroxyestradiol: potential biomarkers for estrogen-initiated cancer. Carcinogenesis. 2001; 22(3):489-97. DOI: 10.1093/carcin/22.3.489. View

Hassan M, Salama S, Zhang D, Arafa H, Hamada F, Fouad H . Gene therapy targeting leiomyoma: adenovirus-mediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model. Fertil Steril. 2009; 93(1):239-50. PMC: 2812608. DOI: 10.1016/j.fertnstert.2008.09.086. View

Otubu J, Buttram V, BESCH N, BESCH P . Unconjugated steroids in leiomyomas and tumor-bearing myometrium. Am J Obstet Gynecol. 1982; 143(2):130-3. DOI: 10.1016/0002-9378(82)90640-8. View

Chiarugi A . Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited. Trends Pharmacol Sci. 2002; 23(3):122-9. DOI: 10.1016/S0165-6147(00)01902-7. View

Wen W, Cai Q, Shu X, Cheng J, Parl F, Pierce L . Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: results from the shanghai breast cancer study and a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2005; 14(2):329-35. DOI: 10.1158/1055-9965.EPI-04-0392. View

Lord R, Bongiovanni B, Bralley J . Estrogen metabolism and the diet-cancer connection: rationale for assessing the ratio of urinary hydroxylated estrogen metabolites. Altern Med Rev. 2002; 7(2):112-29. View

Thirunavukkarasu C, Sakthisekaran D . Effect of selenium on N-nitrosodiethylamine-induced multistage hepatocarcinogenesis with reference to lipid peroxidation and enzymic antioxidants. Cell Biochem Funct. 2001; 19(1):27-35. DOI: 10.1002/cbf.895. View

Andreyko J, Marshall L, Dumesic D, Jaffe R . Therapeutic uses of gonadotropin-releasing hormone analogs. Obstet Gynecol Surv. 1987; 42(1):1-21. View

10.

Eastell R, Colwell A, Hampton L, Reeve J . Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis. J Bone Miner Res. 1997; 12(1):59-65. DOI: 10.1359/jbmr.1997.12.1.59. View

11.

Hamajima N, Matsuo K, Tajima K, Mizutani M, Iwata H, Iwase T . Limited association between a catechol-O-methyltransferase (COMT) polymorphism and breast cancer risk in Japan. Int J Clin Oncol. 2001; 6(1):13-8. DOI: 10.1007/pl00012073. View

12.

Ursin G, London S, Stanczyk F, Gentzschein E, Paganini-Hill A, Ross R . Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1999; 91(12):1067-72. DOI: 10.1093/jnci/91.12.1067. View

13.

Acil Y, Brinckmann J, Notbohm H, Muller P, Batge B . Changes with age in the urinary excretion of hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP). Scand J Clin Lab Invest. 1996; 56(3):275-83. DOI: 10.3109/00365519609088617. View

14.

Dixon D, Flake G, Moore A, He H, Haseman J, Risinger J . Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch. 2002; 441(1):53-62. DOI: 10.1007/s00428-001-0568-7. View

15.

Davis D, Telang N, Osborne M, Bradlow H . Medical hypothesis: bifunctional genetic-hormonal pathways to breast cancer. Environ Health Perspect. 1997; 105 Suppl 3:571-6. PMC: 1469908. DOI: 10.1289/ehp.97105s3571. View

16.

Kabat G, Chang C, Sparano J, Sepkovie D, Hu X, Khalil A . Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev. 1997; 6(7):505-9. View

17.

Ahsan H, Chen Y, Whittemore A, Kibriya M, Gurvich I, Senie R . A family-based genetic association study of variants in estrogen-metabolism genes COMT and CYP1B1 and breast cancer risk. Breast Cancer Res Treat. 2004; 85(2):121-31. DOI: 10.1023/B:BREA.0000025401.60794.68. View

18.

Liu Z, Zhu B . Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells. J Steroid Biochem Mol Biol. 2004; 88(3):265-75. DOI: 10.1016/j.jsbmb.2003.12.003. View

19.

Kocabas N, Sardas S, Cholerton S, Daly A, Karakaya A . Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. Arch Toxicol. 2002; 76(11):643-9. DOI: 10.1007/s00204-002-0387-x. View

20.

Soldani C, Scovassi A . Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis. 2002; 7(4):321-8. DOI: 10.1023/a:1016119328968. View